Trade

with

GenMark Diagnostics Inc
(NASDAQ: GNMK)
AdChoices
9.66
+0.14
+1.47%
After Hours :
9.66
0.00
0.00%

Open

9.61

Previous Close

9.52

Volume (Avg)

226.73k (157.25k)

Day's Range

9.36-9.72

52Wk Range

8.48-14.18

Market Cap.

397.26M

Dividend Rate ( Yield )

-

Beta

0.67

Shares Outstanding

41.73M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Medical Devices
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 27.40M

    • Net Income

    • -33.64M

    • Market Cap.

    • 397.26M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -162.16

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.67

    • Forward P/E

    • -9.86

    • Price/Sales

    • 15.08

    • Price/Book Value

    • 4.35

    • Price/Cash flow

    • -15.20

      • EBITDA

      • -31.05M

      • Return on Capital %

      • -50.69

      • Return on Equity %

      • -59.41

      • Return on Assets %

      • -50.69

      • Book Value/Share

      • 2.22

      • Shares Outstanding

      • 41.73M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 17.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.98

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 25.70

          • 2.66

          • Net Income

            YTD/YTD (last year)

          • -

          • -22.64

          • Net Income

            Q/Q (last year)

          • -

          • -29.83

          • Sales (Revenue)

            5-Year Annual Average

          • 111.53

          • 4.60

          • Net Income

            5-Year Annual Average

          • -

          • -1.34

          • Dividends

            5-Year Annual Average

          • -

          • -0.25

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 43.03

            • 64.08

            • Pre-Tax Margin

            • -161.92

            • 15.19

            • Net Profit Margin

            • -162.16

            • 13.09

            • Average Gross Margin

              5-Year Annual Average

            • -69.50

            • 65.03

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -691.00

            • 17.99

            • Average Net Profit Margin

              5-Year Annual Average

            • -688.70

            • 191.75B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.34

              • Current Ratio

              • 8.02

              • 2.55

              • Quick Ratio

              • 7.83

              • 1.83

              • Interest Coverage

              • -4,596.78

              • 11.70

              • Leverage Ratio

              • 1.15

              • 1.86

              • Book Value/Share

              • 2.22

              • 11.69

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -8.80

                • 34.48

                • P/E Ratio 5-Year High

                • -15.40

                • 224.03

                • P/E Ratio 5-Year Low

                • -2.86

                • 60.23

                • Price/Sales Ratio

                • 14.27

                • 3.20

                • Price/Book Value

                • 4.12

                • 3.23

                • Price/Cash Flow Ratio

                • -15.20

                • 18.66

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -59.41

                    (-536.30)

                  • 12.33

                    (18.16)

                  • Return on Assets %

                    (5-Year Average)

                  • -50.69

                    (-70.40)

                  • 6.62

                    (8.69)

                  • Return on Capital %

                    (5-Year Average)

                  • -59.40

                    (-535.00)

                  • 8.49

                    (11.48)

                  • Income/Employee

                  • -

                  • 34.11k

                  • Inventory Turnover

                  • 6.36

                  • 2.77

                  • Asset Turnover

                  • 0.31

                  • 0.51

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -34.88M
                  Operating Margin
                  -127.28
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -15.20
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  69.07%

                  Mutual Fund Ownership

                  64.26%

                  Float

                  66.47%

                  5% / Insider Ownership

                  3.19%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Putnam Equity Spectrum Fund

                  •  

                    3,533,595

                  • 0.00

                  • 8.46

                  • Fidelity® Select Health Care Portfolio

                  •  

                    2,081,496

                  • -0.43

                  • 4.99

                  • Fidelity® Growth Company Fund

                  •  

                    2,037,853

                  • -0.43

                  • 4.88

                  • Prudential Jennison Health Sciences

                  •  

                    1,777,085

                  • 0.00

                  • 4.26

                  • Parnassus Small Cap Fund

                  •  

                    1,296,280

                  • 29.63

                  • 3.11

                  • MFS® New Discovery Fund

                  •  

                    1,276,403

                  • 0.12

                  • 3.06

                  • Fidelity® Select Medical Equip & Systems

                  •  

                    1,266,906

                  • -0.42

                  • 3.04

                  • T. Rowe Price New Horizons Fund

                  •  

                    1,154,233

                  • -4.27

                  • 2.76

                  • JPM Global Healthcare

                  •  

                    1,051,482

                  • 0.00

                  • 2.52

                  • Artisan Small Cap Fund

                  •  

                    978,882

                  • -5.56

                  • 2.35

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    6,285,955

                  • 0.00%

                  • 15.06

                  • Putnam Investment Management,LLC

                  •  

                    5,198,367

                  • +0.55%

                  • 12.45

                  • Jennison Associates LLC

                  •  

                    3,674,552

                  • -10.04%

                  • 8.80

                  • T. Rowe Price Associates, Inc.

                  •  

                    2,582,354

                  • -2.92%

                  • 6.18

                  • MFS Investment Management K.K.

                  •  

                    2,449,386

                  • +21.01%

                  • 5.87

                  • Artisan Partners Limited Partnership

                  •  

                    2,019,711

                  • -2.15%

                  • 4.84

                  • J.P. Morgan Investment Management Inc.

                  •  

                    1,767,075

                  • -0.81%

                  • 4.23

                  • Adage Capital Partners Gp LLC

                  •  

                    1,650,227

                  • +4.86%

                  • 3.95

                  • Vanguard Group, Inc.

                  •  

                    1,093,631

                  • +4.31%

                  • 2.62

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Medical Devices

                  Type

                  Speculative Growth

                  Style

                  Small Growth

                  GenMark Diagnostics, Inc., was incorporated in the State of Delaware in February 2010. The Company is a molecular diagnostics company developing and commercializing its proprietary eSensor detection technology. Its proprietary electr...moreochemical technology enables fast, accurate and highly sensitive detection of up to 72 distinct biomarkers in a single sample. The Company’s XT-8 System received 510(k) clearance from the Food and Drug Administration and is designed to support molecular diagnostic tests with a compact and easy-to-use workstation and self-contained, disposable test cartridges. Within 30 minutes of receipt of an amplified nucleic acid sample, its XT-8 system produces clear results. The Company’s XT-8 System supports up to 24 test cartridges, of which each could be run independently, result...moreing in a highly convenient and flexible workflow for its customers, which are hospitals and reference laboratories. It intends to expand the use of its XT-8 System and diagnostic tests to those reference laboratories and hospitals in the United States which perform a high volume of molecular diagnostic tests. The Company’s XT-8 System is an automated molecular diagnostic system that enables reference laboratories and hospitals to perform fast, accurate and easy-to-use molecular diagnostic tests. The XT-8 System, which employs its proprietary electrochemical detection technology, consists of a compact bench-top workstation with an integrated touch screen computer and an analyzer into which the self-contained, disposable test cartridges are inserted. The Company’s proprietary eSensor technology is based on the competitive DNA hybridization and electrochemical detection. The Company’s test cartridges are self-contained devices specifically programmed and configured for a given diagnostic test. Each test cartridge includes a sample compartment and a plastic cover that forms a hybridization chamber. The Company’s XT-8 instrument is a multiplex workstation that has a modular design consisting of a base module and up to three test cartridge-processing towers of eight cartridge slots each. It faces competition in the molecular diagnostic testing markets with testing products and systems developed by public and private companies such as Cepheid, Gen-Probe, Inc., Siemens, Hologic, Inc., Innogenetics, Inc, Luminex Corporation, Nanosphere, Inc., Qiagen NV, Roche Diagnostics, a division of F. Hoffmann-La Roche Ltd., Idaho Technologies and Abbott Diagnostics, a division of Abbott Laboratories. The Company’s diagnostic tests also face competition with the LDTs developed by national and regional reference laboratories and hospitals. The design, development, manufacture, testing and sale of its diagnostic products are subject to regulation by numerous governmental authorities, the FDA, and corresponding state and foreign regulatory agencies.lessless

                  Key People

                  Hany Massarany

                  Director/President/CEO

                  Dr. James (Jim) Fox, PhD

                  Chairman of the Board/Director

                  Dr. Jon Faiz Kayyem PhD

                  Senior VP, Divisional/Founder

                  Mr. Scott Mendel

                  CFO

                  Daryl J. Faulkner

                  Director

                  • GenMark Diagnostics Inc

                  • 5964 La Place Court

                  • Carlsbad, CA 92008-8829

                  • USA.Map

                  • Phone: +1 760 448-4300

                  • Fax: +1 760 448-4301

                  • genmarkdx.com

                  Incorporated

                  2010

                  Employees

                  153

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: